

F573 for Injection for the Treatment of Liver Injury/Failure

NCT05689645

Status	RECRUITING
Phase	Phase 2
Sponsor	Beijing Continent Pharmaceutical Co, Ltd.
Enrollment	97 participants

Key Eligibility Criteria

Inclusion (20)

- The first stage:
 - Participants who meet all of the following criteria will be enrolled in the study:
 - Age ≥18 and ≤60 years old, gender is not limited;
 - Patients with liver injury clinically diagnosed with hepatocyte injury or mixed liver injury or CHB patients with hepatitis B virus infection for more than 6 months (refer to the "Chronic Hepatitis B Prevention and Treatment Guidelines (2019 edition)"). Screening patients with CHB may provide etiological (HBsAg positive and/or HBV DNA positive) or clinical or pathological evidence (liver tissue biopsy results) that HBV infection has been present for more than 6 months.
 - Serum ALT: 2~ 10× upper limit of normal (ULN), TBil: <5×ULN;
- ... and 15 more (see full listing online)

Exclusion (48)

- The first stage:
 - Subjects meeting one of the following conditions will not be included in the trial:
 - According to the investigator's judgment, the subjects were patients with cholestatic liver injury;
 - Previous diagnosis of cirrhosis or liver hardness determination (LSM) at screening ≥ 12.4kPa;
 - Patients with severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases, and patients with malignant tumors;
- ... and 43 more (see full listing online)

Locations (10 total)

Beijing You 'an Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Qingyuan People's Hospital (Sixth Affiliated Hospital of Guangzhou Medical University), Qingyuan, Guangdong, China
Shiyan City Taihe Hospital, Shiyan, Hubei, China
... and 7 more locations